Details for Patent: 10,272,046
✉ Email this page to a colleague
Which drugs does patent 10,272,046 protect, and when does it expire?
Patent 10,272,046 protects KALYDECO and TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has twenty patent family members in thirteen countries.
Summary for Patent: 10,272,046
Title: | Pharmaceutical composition and administrations thereof |
Abstract: | The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition. |
Inventor(s): | Dokou; Eleni (Cambridge, MA), Jamzad; Shahla (Belmont, MA), Caesar, Jr.; John P. (Lancaster, MA), Fawaz; Majed (Foxboro, MA), Das; Laura (Charlestown, MA), Gu; Chong-Hui (Waban, MA), Hurter; Patricia Nell (Harvard, MA), Israni; Meghna Jai (Boston, MA), Johnston; Meghan M. (Wakefield, MA), Knezic; Dragutin (Watertown, MA), Kuzmission; Andrew G. (Shrewsburg, MA), Wang; HongRen (Lexington, MA) |
Assignee: | Vertex Pharmaceuticals Incorporated (Boston, MA) |
Application Number: | 15/181,114 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,272,046 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 10,272,046
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-004 | May 3, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-005 | May 3, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-003 | Apr 29, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-001 | Mar 17, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | KALYDECO | ivacaftor | GRANULE;ORAL | 207925-002 | Mar 17, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,272,046
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2013226076 | ⤷ Try a Trial | |||
Brazil | 112014021090 | ⤷ Try a Trial | |||
Canada | 2865519 | ⤷ Try a Trial | |||
China | 104470518 | ⤷ Try a Trial | |||
China | 109966264 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |